TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oramed Pharm ( (ORMP) ) has provided an announcement.
On November 16, 2025, Oramed Pharmaceuticals’ Board of Directors declared a dividend of one common stock purchase right for each outstanding share of common stock, payable on November 27, 2025. This Rights Agreement is designed to protect shareholders in the event of a hostile takeover by ensuring fair treatment and enhancing the Board’s negotiation capabilities. The Rights become exercisable if a person or group acquires 15% or more of the company’s stock, allowing holders to purchase shares at a favorable rate, while the Rights held by the acquiring party become void. The Rights will expire three years after adoption unless redeemed or exchanged earlier.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
Oramed Pharm’s overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. is a pioneer in the field of oral delivery solutions for drugs that are traditionally administered via injection. The company’s novel Protein Oral Delivery (POD™) technology aims to protect drug integrity and enhance absorption.
Average Trading Volume: 119,877
Technical Sentiment Signal: Hold
Current Market Cap: $92.74M
For a thorough assessment of ORMP stock, go to TipRanks’ Stock Analysis page.